These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32811803)

  • 21. Interleukin-12. Biologic activity, therapeutic utility, and role in disease.
    Hendrzak JA; Brunda MJ
    Lab Invest; 1995 Jun; 72(6):619-37. PubMed ID: 7783421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy of cancer with interleukin-12.
    Mazzolini G; Prieto J; Melero I
    Curr Pharm Des; 2003; 9(24):1981-91. PubMed ID: 12871184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy.
    Gordon MS
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S96-8. PubMed ID: 8765426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo.
    Quesniaux VF; Wehrli S; Steiner C; Joergensen J; Schuurman HJ; Herrman P; Schreier MH; Schuler W
    Blood; 1994 Sep; 84(5):1543-52. PubMed ID: 7520778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma.
    Lo CH; Chang CM; Tang SW; Pan WY; Fang CC; Chen Y; Wu PY; Chen KY; Ma HI; Xiao X; Tao MH
    J Gene Med; 2010 May; 12(5):423-34. PubMed ID: 20440753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
    Dhupkar P; Gordon N
    Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical use of systemic IL-12 therapy.
    Gollob JA; Mier JW; Atkins MB
    Cancer Chemother Biol Response Modif; 2001; 19():353-69. PubMed ID: 11686023
    [No Abstract]   [Full Text] [Related]  

  • 28. New insights into IL-12-mediated tumor suppression.
    Tugues S; Burkhard SH; Ohs I; Vrohlings M; Nussbaum K; Vom Berg J; Kulig P; Becher B
    Cell Death Differ; 2015 Feb; 22(2):237-46. PubMed ID: 25190142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
    Vadhan-Raj S
    Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble CD4, soluble CD8, soluble CD25, lymphopoieitic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation.
    Ho AD; Maruyama M; Maghazachi A; Mason JR; Glück S; Corringham RE
    Blood; 1994 Nov; 84(10):3550-7. PubMed ID: 7949110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism of interleukin 12, interleukin 3 and serum factor on primitive human hematopoietic progenitor cells.
    Hirao A; Takaue Y; Kawano Y; Sato J; Suzue T; Abe T; Saito S; Kawahito M; Okamoto Y; Makimoto A
    Stem Cells; 1995 Jan; 13(1):47-53. PubMed ID: 7536512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of interleukin-1 in hematopoiesis.
    Fibbe WE; Willemze R
    Acta Haematol; 1991; 86(3):148-54. PubMed ID: 1785229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localized Nano-mediated Interleukin-12 Gene Therapy: Promising Candidate for Cancer Immunotherapeutics.
    Venkatas J; Singh M
    Curr Cancer Drug Targets; 2022; 22(10):825-842. PubMed ID: 35692136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.
    Burdelya L; Catlett-Falcone R; Levitzki A; Cheng F; Mora LB; Sotomayor E; Coppola D; Sun J; Sebti S; Dalton WS; Jove R; Yu H
    Mol Cancer Ther; 2002 Sep; 1(11):893-9. PubMed ID: 12481410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of chemotherapy antineoplastic agents with biologic agents: enhancement of antitumor activities by interleukin-1.
    Johnson CS
    Curr Opin Oncol; 1992 Dec; 4(6):1108-15. PubMed ID: 1457525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergism of interleukin-12 and interleukin-3 on development of hematopoietic progenitors.
    Fardoun-Joalland D; Teixeira-Lebrun G; Lenormand B; Dzondo-Gadet M; Vannier JP
    Eur J Haematol; 1995 Mar; 54(3):172-5. PubMed ID: 7720837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The potential of interleukin-12 for use in cancer therapy].
    Gately MK; Brunda MJ
    Gan To Kagaku Ryoho; 1996 Jul; 23(8):961-71. PubMed ID: 8687231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-12, an emerging anti-tumour cytokine.
    Hiscox S; Jiang WG
    In Vivo; 1997; 11(2):125-32. PubMed ID: 9179604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential use of recombinant human interleukin-6 in clinical oncology.
    Veldhuis GJ; Willemse PH; Mulder NH; Limburg PC; De Vries EG
    Leuk Lymphoma; 1996 Feb; 20(5-6):373-9. PubMed ID: 8833392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.